Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4.Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4.We present a case of grade Wooden Figure 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanom